Continue CT with 30 ongoing Indian subjects: CDSCO panel tells Novo-Nordisk on Insulin Icodec
New Delhi: Based on the safety data of 30 Indian subjects in the global clinical trial of Insulin Icodec, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to drug major Novo Nordisk for the continuation of the trial of the antidiabetic drug Insulin Icodec with already […] More